I'm LongbridgeAI, I can summarize articles.Pfizer (PFE) fell 2.57% this week to close at $27.72, underperforming the S&P 500 by about 1.77 percentage points; the benchmark was down 0.8%. The stock opened Tuesday (Sep 8) at $28.015, hit a weekly high of $28.145, then drifted lower over the following sessions. Thursday (Sep 10) marked the weekly low at $27.400 before Friday (Sep 11) settled at $27.720. Weekly amplitude was 2.66%, and average daily volume of 28.
The Week
Pfizer (PFE) fell 2.57% this week to close at $27.72, underperforming the S&P 500 by about 1.77 percentage points; the benchmark was down 0.8%. The stock opened Tuesday (Sep 8) at $28.015, hit a weekly high of $28.145, then drifted lower over the following sessions. Thursday (Sep 10) marked the weekly low at $27.400 before Friday (Sep 11) settled at $27.720. Weekly amplitude was 2.66%, and average daily volume of 28.82m shares ran about 26% below the 60-day median, pointing to a quiet tape.
Key Events
Pfizer itself had no major product approvals or regulatory milestones this week. The story was mostly external. On Monday (Sep 7), Pfizer showed up on a list of pharma stocks to watch. Tuesday (Sep 8) brought an invitation to a healthcare conference webcast, while Novartis India announced a $132m acquisition of certain Pfizer brands — a limited asset sale. By Wednesday (Sep 9), commentary began comparing Pfizer with other dividend names, framing the current yield as not the most attractive option. On Thursday (Sep 10), TwoStep Therapeutics closed a $62.5m Series A led by Insight Partners and Medical Excellence Capital, with Merck’s M Ventures co-leading; Pfizer was not involved. Friday (Sep 11) saw Novavax flag Sanofi and Pfizer as catalysts in its Matrix-M platform pivot, adding a partner-related note without new Pfizer-specific news.
Analyst Ratings
Across 28 institutions covering Pfizer, 8 rate it buy, 2 overweight, 16 hold, 1 underweight and 1 sell. The consensus rating is buy, with a consensus target of $28.875 — about 4.17% above the latest close of $27.72. The target range runs from $25.000 to $35.750, a wide spread that reflects real disagreement on Pfizer’s medium-term outlook. Within the pharmaceutical industry, Pfizer ranks 4th out of 206 names on analyst rating strength.
The Week Ahead
Macro data dominates next week. Tuesday (Sep 15) brings the New York Fed manufacturing index, with a prior reading of 20.6 and a forecast of 14.75. Wednesday (Sep 16) packs US retail sales, retail sales ex-autos, import price index, NAHB housing market index and EIA weekly crude inventories. For Pfizer, these matter mostly through rates and sector rotation, but the nearer-term watch is whether healthcare conference discussions translate into pipeline or revenue momentum, and how peer clinical news shapes pharma sentiment.
In Short
Pfizer’s week was quiet: the stock slipped modestly and lagged the broader market on below-average volume, suggesting limited participation. The analyst picture stays broadly positive with a buy consensus, yet buy-rated coverage is not overwhelming and the target range is wide. Asset-level news included a small brand sale, while dividend commentary compared Pfizer unfavourably against alternatives; the dividend yield sits at 6.20% with a P/E around 36.45x. The tension lies between a supportive rating stance and an otherwise muted tape. The next test is whether conference signals feed into fundamentals, and how next week’s macro data shifts rate expectations and sector rotation.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.